Abstract: Doxorubicin (DOX), an anthracycline antibiotic, remains a cornerstone in the chemotherapeutic management of various solid and hematological malignancies. Despite its potent anti-tumor efficacy, the clinical utility of DOX is severely hindered by dose-dependent toxicities—most notably irreversible cardiotoxicity—and the rapid development of multidrug resistance (MDR). This comprehensive literature review explores the pharmacological activity and molecular mechanisms of DOX, emphasizing the complex pathways driving chemoresistance, including the overexpression of ATP-binding cassette (ABC) transporters, dysregulation of apoptosis (e.g., p53 mutation), activation of the Nrf2 antioxidant pathway, and the influence of non-coding RNAs and the tumor microenvironment. Furthermore, this review highlights emerging strategies for chemoresistance reversal. These include the co-administration of DOX with phytochemicals (such as curcumin, quercetin, and resveratrol), the development of advanced nanoscale drug delivery systems (liposomes, polymeric micelles, and hydrogels), and innovative approaches like gene editing (CRISPR-Cas9) and photothermal therapy. By targeting specific resistance mechanisms and improving site-specific delivery, these novel oncologic strategies aim to maximize the therapeutic impact of DOX while minimizing systemic harm.
1. Introduction
Doxorubicin (DOX), commonly known by its trade name Adriamycin, is a highly effective anthracycline chemotherapeutic agent originally isolated from Streptomyces peucetius [35]. Since its clinical approval, DOX has been extensively utilized as a first-line treatment for a wide spectrum of cancers, including breast, ovarian, bladder, lung, thyroid, soft tissue sarcomas, and hematological malignancies such as leukemia and Hodgkin's lymphoma [4][11][20]. Despite its broad-spectrum efficacy, the long-term clinical success of DOX is compromised by two major challenges: severe, cumulative dose-dependent cardiotoxicity and the emergence of chemoresistance [1][4]. Chemoresistance can be intrinsic or acquired and often leads to treatment failure, tumor recurrence, and metastasis [4]. Consequently, contemporary oncological research is heavily focused on elucidating the underlying mechanisms of DOX resistance and developing innovative strategies—ranging from combination therapies with natural compounds to advanced nanomedicine—to reverse resistance and widen the therapeutic window of this essential drug [1][8].
2. Pharmacological Activity
The pharmacological activity of DOX is characterized by its pleiotropic effects on cancer cells. DOX primarily functions by entering the cell and localizing within the nucleus and mitochondria, where it disrupts cellular replication and induces cell death [16][17]. The drug triggers multiple pathways of cytotoxicity, including apoptosis, autophagy, senescence, ferroptosis, and pyroptosis [13]. However, DOX is not entirely cell-selective, leading to significant adverse effects on healthy tissues. The most prominent dose-limiting toxicity is cardiotoxicity, which can manifest as progressive and irreversible cardiomyopathy and congestive heart failure [4][27]. This cardiac damage is primarily driven by oxidative stress, mitochondrial dysfunction, calcium dyshomeostasis, and the formation of DOX-iron complexes [1][4]. Additionally, DOX treatment has been linked to gastrointestinal toxicity, hepatotoxicity, nephrotoxicity, and chemotherapy-induced cognitive impairment (neurotoxicity or "chemobrain") [31][38][42]. Recent studies also suggest that DOX-induced dysbiosis of the gut microbiota may play a role in the perpetuation of cardiac injury via the gut-heart axis [33].
3. Molecular Mechanism of Action
The primary anti-tumor mechanisms of DOX involve its intercalation into the DNA helix, which prevents DNA replication and RNA synthesis, and the inhibition of topoisomerase II, leading to double-stranded DNA breaks [4][27]. DOX also induces histone eviction from open chromatin and generates high levels of reactive oxygen species (ROS) through its conversion into an unstable semiquinone intermediate, causing severe oxidative damage to lipids, proteins, and DNA [4][11][23].
Conversely, cancer cells develop resistance to DOX through a highly complex, multifactorial network of mechanisms:
- Drug Efflux Transporters: The most well-documented mechanism is the overexpression of ATP-binding cassette (ABC) transporters, particularly P-glycoprotein (P-gp/ABCB1), breast cancer resistance protein (BCRP/ABCG2), and multidrug resistance-associated proteins (MRP1/ABCC1, ABCC2) [11][19][34]. These pumps actively extrude DOX from the intracellular space, reducing its concentration below therapeutic levels.
- Signaling Pathways and Oxidative Stress Defense: Activation of the Nuclear factor erythroid 2-related factor 2 (Nrf2) pathway protects cancer cells from DOX-induced oxidative stress, promoting survival and resistance [3]. Other survival cascades, including the PI3K/AKT/mTOR, JAK/STAT, and MAPK/ERK pathways, are frequently upregulated in resistant cells [1][11].
- Genetic and Epigenetic Alterations: Mutation or inactivation of the p53 tumor suppressor gene is a primary cause of DOX resistance, as it impairs the cell's ability to undergo apoptosis in response to DNA damage [4]. Additionally, the overexpression of Heat shock protein 27 (Hsp27) facilitates proteostasis and inhibits apoptosis [35].
- Non-Coding RNAs: Long non-coding RNAs (lncRNAs) and microRNAs (miRNAs) critically regulate resistance. For instance, lncRNAs such as H19, TUG1, and LINC01116, as well as miRNAs (e.g., miR-223, miR-124, miR-99a-5p), modulate the expression of ABC transporters, apoptosis-related genes, and epithelial-to-mesenchymal transition (EMT) markers [8][17][19][41].
- Metabolic Reprogramming and Tumor Microenvironment: Resistant cells often exhibit enhanced glycolysis driven by enzymes like Sphingosine kinase 1 (SphK1) [8]. Furthermore, hypoxic conditions (mediated by HIF-1α) and interactions with cancer-associated fibroblasts (CAFs) in the tumor microenvironment shield cells from DOX-induced apoptosis [14][22].
4. Structure-Activity Relationship (SAR)
The structural properties of DOX dictate both its efficacy and its metabolic fate. DOX undergoes metabolic carbonyl reduction catalyzed by aldo-keto reductases and carbonyl reductases to form doxorubicinol (DOXol) [10]. DOXol is significantly less active against tumors but is highly cardiotoxic, compounding cardiac injury while contributing to the resistant phenotype [10][14]. To overcome resistance and toxicity, structural modifications and prodrug strategies have been developed. For example, Cathepsin B-cleavable DOX prodrugs exploit the overexpression of specific proteases in the tumor microenvironment to selectively release the active drug [30]. Furthermore, conjugating DOX to polymers or encapsulating it within nanocarriers (e.g., liposomes, micelles) alters its pharmacokinetic profile. These macromolecular structures bypass P-gp-mediated efflux through endocytotic cellular uptake, thereby increasing intracellular drug accumulation and circumventing a primary mechanism of resistance [11][14].
5. Current Limitations
Despite its efficacy, the clinical application of DOX is severely restricted by several limitations. The most critical is its dose-dependent cardiotoxicity, which caps the lifetime cumulative dose a patient can safely receive (typically around 400 mg/m²) [1]. Secondly, the rapid acquisition of MDR renders the drug ineffective over time. The heterogeneity of tumors, the presence of cancer stem cells (CSCs), and the dynamic adaptation of the tumor microenvironment make it exceedingly difficult to eradicate the disease with DOX alone [14][19]. Additionally, DOX suffers from poor oral bioavailability due to low paracellular permeability and extensive intestinal P-gp efflux, necessitating intravenous administration [11]. Finally, pharmacogenetic variations—such as polymorphisms in genes encoding cytochrome P450 enzymes (CYP3A4, CYP2D6) and the MDR1 protein—result in significant inter-patient variability regarding both drug efficacy and the severity of adverse reactions [38].
6. Future Perspectives
To maximize the therapeutic impact of DOX while minimizing harm, future research is heavily invested in chemoresistance reversal and targeted delivery strategies:
- Combination Therapies with Phytochemicals: Co-administration of DOX with natural compounds has shown immense promise. Phytochemicals such as curcumin, quercetin, resveratrol, luteolin, and wogonin act as potent chemosensitizers. They function by downregulating P-gp expression, inhibiting the Nrf2 and PI3K/AKT pathways, and suppressing EMT, thereby restoring DOX sensitivity and simultaneously offering cardioprotective antioxidant effects [3][8][9][25].
- Advanced Nanomedicine: The development of multifunctional nanoplatforms—including PEGylated liposomes, polymeric micelles, chitosan nanoparticles, and injectable hydrogels—enables the targeted co-delivery of DOX and resistance modulators [5][14][23][26]. Stimuli-responsive nanocarriers (sensitive to pH, redox, or near-infrared light) ensure that DOX is released specifically within the acidic and reductive tumor microenvironment, drastically reducing systemic toxicity [11][26].
- Gene and Targeted Therapies: Gene-editing tools like CRISPR-Cas9 are being explored to knock out resistance genes (e.g., ABCB1) directly [1][28]. Additionally, gene therapy approaches aiming to restore p53 function in combination with DOX have demonstrated synergistic tumor elimination [1].
- Photothermal and Immunotherapy Combinations: Combining DOX with photothermal therapy (using gold nanoparticles or carbon nanotubes) induces localized hyperthermia, which enhances DOX uptake and cytotoxicity [1]. Furthermore, integrating DOX with immune checkpoint inhibitors (e.g., anti-PD-1) is currently in clinical trials, showing potential to boost the anti-tumor immune response [1].
Ultimately, the integration of pharmacogenomics to tailor DOX regimens to individual genetic profiles, combined with these advanced delivery and sensitization strategies, represents the future of personalized, highly effective, and safe anthracycline-based oncology [1][38].
